PlasmaGen raises ₹150 crore, valuation crosses ₹1,500 crore
The Indian biotechnology sector has been witnessing significant growth in recent years, with several startups and companies raising substantial funds to support their research and development activities. One such company that has been making waves in the industry is PlasmaGen Biosciences, a Bengaluru-based firm that has been working on developing innovative plasma-based therapies. In a recent development, PlasmaGen has raised ₹150 crore in a funding round led by ViNS Bioproducts, valuing the company at over ₹1,500 crore.
This funding round is a significant milestone for PlasmaGen, which has been backed by prominent investors such as Eight Roads, FIL Capital, and F-Prime. To date, the company has raised over ₹600 crore, demonstrating the confidence of investors in its mission and vision. The funds raised will be utilized to further expand PlasmaGen’s research and development capabilities, as well as to enhance its manufacturing infrastructure.
One of the key areas of focus for PlasmaGen is the development of plasma fractionation facilities, which are critical for the production of life-saving therapies. The company operates one of India’s five plasma fractionation facilities near Bengaluru, which is equipped with state-of-the-art technology and equipment. This facility enables PlasmaGen to produce high-quality plasma products, including immunoglobulins, albumin, and clotting factors, which are used to treat a range of diseases and disorders.
The demand for plasma-based therapies is increasing rapidly, driven by the growing prevalence of diseases such as immunodeficiency disorders, bleeding disorders, and infectious diseases. PlasmaGen is well-positioned to capitalize on this trend, with its strong research and development capabilities, as well as its robust manufacturing infrastructure. The company’s products are used by hospitals and healthcare providers across India, and it has established a strong reputation for quality and reliability.
The funding round led by ViNS Bioproducts is a testament to the growth potential of PlasmaGen and the Indian biotechnology sector as a whole. The investment will enable the company to accelerate its research and development activities, as well as to expand its manufacturing capacity to meet the growing demand for plasma-based therapies. With its strong backing from prominent investors, PlasmaGen is poised to become a leading player in the global biotechnology industry.
The Indian biotechnology sector has been witnessing significant growth in recent years, driven by the government’s initiatives to promote innovation and entrepreneurship. The sector has attracted significant investments from domestic and international investors, and several Indian companies have established themselves as leaders in the global market. PlasmaGen is one such company that has been making significant strides in the industry, and its recent funding round is a testament to its growth potential.
The company’s success can be attributed to its strong focus on research and development, as well as its commitment to producing high-quality products. PlasmaGen’s team of scientists and researchers is dedicated to developing innovative plasma-based therapies that can address the unmet medical needs of patients. The company’s products have been widely accepted by healthcare providers across India, and it has established a strong distribution network to ensure that its products reach patients in a timely and efficient manner.
In addition to its focus on research and development, PlasmaGen has also been investing in its manufacturing infrastructure. The company’s plasma fractionation facility near Bengaluru is equipped with state-of-the-art technology and equipment, and it has been designed to meet the highest standards of quality and safety. The facility is capable of producing a range of plasma products, including immunoglobulins, albumin, and clotting factors, which are used to treat a range of diseases and disorders.
The funding round led by ViNS Bioproducts will enable PlasmaGen to further expand its manufacturing capacity, as well as to invest in new research and development projects. The company is planning to launch new products in the near future, which will address the unmet medical needs of patients in India and around the world. With its strong backing from prominent investors, PlasmaGen is poised to become a leading player in the global biotechnology industry.
In conclusion, the recent funding round by PlasmaGen Biosciences is a significant milestone for the Indian biotechnology sector. The company’s success is a testament to the growth potential of the sector, and it demonstrates the confidence of investors in the mission and vision of Indian biotechnology companies. With its strong focus on research and development, as well as its commitment to producing high-quality products, PlasmaGen is poised to become a leading player in the global biotechnology industry.
News Source: https://ascendants.in/funding-feed/plasmagen-biosciences-raises-rs-150-cr/
About the Author
